Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Y1ZU
|
||||
| Former ID |
DIB006726
|
||||
| Drug Name |
SA-237
|
||||
| Synonyms |
Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai
|
||||
| Indication | Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] | Phase 3 | [1] | ||
| Company |
Chugai Pharmaceutical Co Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-6 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| HIF-1 signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Jak-STAT signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Reactome | MAPK3 (ERK1) activation | ||||
| MAPK1 (ERK2) activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Senescence and Autophagy in Cancer | |||||
| IL-6 signaling pathway | |||||
| Differentiation Pathway | |||||
| Interleukin-6 signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02073279) Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD. U.S. National Institutes of Health. | ||||
| REF 2 | IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.